Rocket Pharmaceuticals (NASDAQ:RCKT) Cut to Hold at Leerink Partnrs

Leerink Partnrs downgraded shares of Rocket Pharmaceuticals (NASDAQ:RCKT - Free Report) from a strong-buy rating to a hold rating in a research note published on Tuesday morning,Zacks.com reports. Leerink Partnrs also issued estimates for Rocket Pharmaceuticals' Q2 2025 earnings at ($0.56) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.20) EPS, FY2026 earnings at ($1.94) EPS and FY2027 earnings at ($1.78) EPS.

Several other research analysts have also commented on the stock. JPMorgan Chase & Co. restated a "neutral" rating on shares of Rocket Pharmaceuticals in a report on Wednesday. Chardan Capital cut their price target on shares of Rocket Pharmaceuticals from $46.00 to $17.00 and set a "buy" rating on the stock in a report on Wednesday. Morgan Stanley reaffirmed an "equal weight" rating and issued a $7.00 price objective on shares of Rocket Pharmaceuticals in a research report on Wednesday. Jefferies Financial Group reaffirmed a "hold" rating on shares of Rocket Pharmaceuticals in a research report on Wednesday. Finally, BMO Capital Markets lowered their price objective on shares of Rocket Pharmaceuticals from $30.00 to $8.00 and set an "outperform" rating for the company in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $21.21.

Rocket Pharmaceuticals Trading Down 5.3%

NASDAQ RCKT traded down $0.14 during mid-day trading on Tuesday, hitting $2.48. The company's stock had a trading volume of 7,402,317 shares, compared to its average volume of 1,873,470. Rocket Pharmaceuticals has a 52-week low of $2.19 and a 52-week high of $26.98. The stock's fifty day simple moving average is $6.20 and its two-hundred day simple moving average is $9.49. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.05 and a quick ratio of 6.05. The firm has a market capitalization of $264.83 million, a P/E ratio of -0.90 and a beta of 1.02.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.02. During the same quarter in the previous year, the business posted ($0.66) earnings per share. Research analysts expect that Rocket Pharmaceuticals will post -2.83 EPS for the current year.

Insider Transactions at Rocket Pharmaceuticals

In other Rocket Pharmaceuticals news, CEO Gaurav Shah acquired 20,000 shares of the firm's stock in a transaction on Thursday, April 10th. The stock was purchased at an average price of $5.08 per share, with a total value of $101,600.00. Following the completion of the acquisition, the chief executive officer now directly owns 792,680 shares in the company, valued at $4,026,814.40. This trade represents a 2.59% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Kinnari Patel acquired 21,099 shares of the firm's stock in a transaction on Wednesday, April 9th. The stock was acquired at an average cost of $4.70 per share, with a total value of $99,165.30. Following the acquisition, the insider now owns 26,774 shares of the company's stock, valued at $125,837.80. This trade represents a 371.79% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 24.76% of the company's stock.

Hedge Funds Weigh In On Rocket Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers boosted its holdings in shares of Rocket Pharmaceuticals by 1.3% during the fourth quarter. Rhumbline Advisers now owns 99,339 shares of the biotechnology company's stock valued at $1,249,000 after acquiring an additional 1,242 shares during the period. Envestnet Asset Management Inc. boosted its holdings in shares of Rocket Pharmaceuticals by 4.1% during the fourth quarter. Envestnet Asset Management Inc. now owns 32,422 shares of the biotechnology company's stock valued at $408,000 after acquiring an additional 1,280 shares during the period. Arizona State Retirement System boosted its holdings in shares of Rocket Pharmaceuticals by 8.4% during the fourth quarter. Arizona State Retirement System now owns 19,826 shares of the biotechnology company's stock valued at $249,000 after acquiring an additional 1,528 shares during the period. Virtus ETF Advisers LLC boosted its holdings in shares of Rocket Pharmaceuticals by 40.4% during the fourth quarter. Virtus ETF Advisers LLC now owns 5,656 shares of the biotechnology company's stock valued at $71,000 after acquiring an additional 1,628 shares during the period. Finally, Victory Capital Management Inc. boosted its holdings in shares of Rocket Pharmaceuticals by 16.1% during the first quarter. Victory Capital Management Inc. now owns 11,929 shares of the biotechnology company's stock valued at $80,000 after acquiring an additional 1,658 shares during the period. Institutional investors and hedge funds own 98.39% of the company's stock.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.